Trastuzumab for Breast Cancer
This trial is testing copanlisib given with trastuzumab and pertuzumab to see if it is effective and has manageable side effects in treating patients with advanced HER2 positive breast cancer.
- Breast Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many participants have registered for this clinical study?
"Affirmative, according to the data hosted by clinicaltrials.gov this experiment commenced on December 6th 2019 and is still actively enrolling candidates. 12 participants need to be admitted from two separate sites."
Are there any vacancies from the research study still available for potential participants?
"Affirmative. Clinicaltrials.gov records verify that this medical trial was initially advertised on December 6th 2019 and has been continuously updated since then. Currently, 12 patients are being sought from two distinct sites for the study to progress."
What other experiments have employed Trastuzumab to assess its efficacy?
"Trastuzumab was initially trialed in 1999 at Ospedale di Circolo e Fondazione Macchi. Since then, 392 studies have been completed and there are currently 224 active experiments recruiting participants, many of which occur around Houston, Texas."
To what diseases is Trastuzumab routinely prescribed?
"Trastuzumab is frequently prescribed to treat brca1 gene mutations, however it has also been used for therapeutic procedure, inflammatory [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) (IBC), and general cases of breast malignancy."